DEA Breaks Silence on Marijuana Grower Applications

We previously reported on a unique lawsuit filed this summer by Scottsdale Research Institute, LLC (SRI) against the Drug Enforcement Administration (DEA). By filing a petition for writ of mandamus, SRI sought to compel the DEA to take action on its application to grow cannabis for clinical research, which was filed in 2016. With a deadline to respond to SRI’s petition looming just two days away, the DEA announced on Monday that it is “providing notice of pending applications from entities applying to be…
Continue reading...

FDA’s Opinion: CBD You in April…Maybe.

On Wednesday, February 27, 2019, FDA Commissioner Scott Gottlieb, MD, testified before Congress. He testified that the agency planned a public meeting in April to begin a rule making procedure on CBD. The goal is to create “an appropriately efficient and predictable regulatory framework for regulating CBD products,” he said. This is good news for those in the hemp and cannabis market. Unfortunately, the statement also means that CBD infused products are still illegal in the U.S. Dr. Gottlieb’s testimony is further evidence of the…
Continue reading...